Methyl 2-(3-(hydroxymethyl)piperidin-1-yl)nicotinate hydrochloride

Catalog No. :
ACBDWD577
CAS No. :
1185312-53-1
Molecular Formula :
C13H19ClN2O3
Molecular Weight :
286.76

IUPAC Name:methyl 2-(3-(hydroxymethyl)piperidin-1-yl)nicotinate hydrochloride

Methyl 2-(3-(hydroxymethyl)piperidin-1-yl)nicotinate hydrochloride structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
1g95%$425.00Login to see priceInquiryInquiry

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product NameMethyl 2-(3-(hydroxymethyl)piperidin-1-yl)nicotinate hydrochloride
IUPAC Namemethyl 2-(3-(hydroxymethyl)piperidin-1-yl)nicotinate hydrochloride
MDL No.MFCD09607871
Molecular FormulaC13H19ClN2O3
Molecular Weight286.76
SMILESO=C(OC)C1=C(N2CC(CO)CCC2)N=CC=C1.[H]Cl
InChI KeyCKLIHYULYBHAPH-UHFFFAOYSA-N
Synonym3-HydroxyMethyl-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-3'-carboxylic acid Methyl ester hydrochloride, 98+% C13H19ClN2O3, MW: 286.76;2-[3-(Hydroxymethyl)-1-piperidinyl]-3-pyridinecarboxylic acid methyl ester hydrochloride;3-Hydroxymethyl-3,4,5,6-tetrahydro-2H-[1,2]bipyridinyl-3-carboxylic acid met;methyl 2-[3-(hydroxymethyl)piperidin-1-yl]pyridine-3-carboxylate
CAS No.1185312-53-1

Safety Data

Pictogram
Harmful or irritant
Signal Word
Achtung
Hazard Statement(s)
H302-H315-H319-H335
Precautionary Statement(s)
P261-P264-P270-P271-P280-P302+P352-P304+P340-P305+P351+P338-P312-P330-P362-P403+P233-P501

Synthetic Route by SureRoute

1. ACBDWD577 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Then
  3. ACBDWD577 route product structure diagram
    ACBDWD5771185312-53-1
Inquiry

2. ACBDWD577 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Then
  3. ACBDWD577 route product structure diagram
    ACBDWD5771185312-53-1
Inquiry

Comments (0)